New Boston office strengthens position in US market, providing local support and greater responsiveness for clinical trials
The Banook Group, specialised in cardiac safety, clinical imaging and endpoint adjudication, announces the opening of its first US office in Boston, Massachusetts. This is the third international office for Banook since its inception in 1999, adding to its headquarters in Nancy (France), and locations in Munich (Germany) and Montreal (Canada).
About 40% of Banook’s customers are based in the US. The opening of the Boston office aims to reduce the constraints of time zones and to provide enhanced technical and logistics support.
It will allow the company to offer local support to its 70 current US customers and to grow in the North American market. This follows the opening of a Canadian office in 2017, increasing availability across the North American continent to meet clients’ needs.
“Our team is very excited about this next logical step,” said Alexandre Durand-Salmon, CEO of the Banook Group. “Our high-quality core lab services are designed to fit the rapidly evolving needs of our clients today. A local presence gives us the right edge to establish ourselves as industry experts in the US. We have received terrific support and expressions of interest from prospects and customers who have been trying to source these types of turnkey services.”
These clients and prospects are laboratories and CROs wishing to measure the cardiac safety of their molecules; also to centralise their medical imaging and endpoint adjudication, and to conduct virtual clinical trial projects, which have been increasing in number since COVID-19.
The Banook Group has developed a complete clinical study support process, including project setup and management; offering logistics, devices, support and analysis by experts up to and including conclusion with data management.
This new point of contact confirms Banook’s objective to be close to its clients, both geographically and in terms of clinical project management.
With 32% of global clinical trials located in the United States, this will allow the Group to be even more reactive in the follow-up of clinical studies in this dynamic market.
The North American clinical trials market forecasts a CAGR of 7.4% during the period of 2022-2027, with 11,865 active clinical trials in 2020, across various phases for cancer indications.